[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![PrismMarketView Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1257318598386696195.png) PRISM MarketView [@PrismMarketView](/creator/twitter/PrismMarketView) on x 4693 followers
Created: 2025-06-30 14:23:12 UTC

Tango Therapeutics (NASDAQ: $TNGX) has dosed the first patient in its Phase 1/2 trial of TNG462 plus Revolution Medicines’ RAS inhibitors for MTAP-deleted pancreatic and lung cancers. Backed by strong preclinical data and $216M in cash, HC Wainwright sees more room to run with a $XX price target.
@TangoTxOncology 


![](https://pbs.twimg.com/media/Gusq0hCWgAAChYE.jpg)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1939691189784957332/c:line.svg)

**Related Topics**
[hc](/topic/hc)
[$216m](/topic/$216m)
[$tngx](/topic/$tngx)
[nasdaq](/topic/nasdaq)
[$rvmd](/topic/$rvmd)

[Post Link](https://x.com/PrismMarketView/status/1939691189784957332)